Veradermics, Incorporated Asset Resilience Ratio
Veradermics, Incorporated asset resilience ratio. Veradermics, Incorporated (MANE) has an Asset Resilience Ratio of 55.79% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Veradermics, Incorporated liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Veradermics, Incorporated (2024–2025)
Asset resilience ratio of Veradermics, Incorporated from 2024 to 2025. This chart shows how Veradermics, Incorporated's Asset Resilience Ratio has changed over time. Read MANE total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Veradermics, Incorporated's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Veradermics, Incorporated total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $222.38 Million | 55.79% |
| Total Liquid Assets | $222.38 Million | 55.79% |
Asset Resilience Insights
- Very High Liquidity: Veradermics, Incorporated maintains exceptional liquid asset reserves at 55.79% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Veradermics, Incorporated Industry Peers by Asset Resilience Ratio
Compare Veradermics, Incorporated's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Veradermics, Incorporated Asset Resilience Ratio by Year (2024–2025)
Veradermics, Incorporated asset resilience ratio by year from 2024 to 2025. The table below shows the annual Asset Resilience Ratio data for Veradermics, Incorporated.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 78.69% | $120.10 Million | $152.62 Million | -- |
| 2024-12-31 | 0.00% | $0.00 | $59.38 Million | -- |
About Veradermics, Incorporated
Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in t… Read more